Related Experiment Video

Updated: Dec 24, 2025

An In Vitro System to Study Tumor Dormancy and the Switch to Metastatic Growth
09:14

An In Vitro System to Study Tumor Dormancy and the Switch to Metastatic Growth

Published on: August 11, 2011

16.2K

TIE2 Induces Breast Cancer Cell Dormancy and Inhibits the Development of Osteolytic Bone Metastases

Florian Drescher1,2, Patricia Juárez1, Danna L Arellano1,2

  • 1Biomedical Innovation Department, Centro de Investigación Científica y de Educación Superior de Ensenada (CICESE), Ensenada, Baja California 22860, Mexico.

Cancers
|April 9, 2020
PubMed

Insights

The tyrosine kinase receptor TIE2 promotes breast cancer dormancy in bone, increasing patient survival. Inhibiting TIE2 may awaken dormant cancer cells, suggesting caution in anti-angiogenic treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Metastasis

Background:

  • Breast cancer (BCa) bone metastases can remain dormant for years, evading treatment.
  • The tyrosine kinase receptor TIE2 is known to induce hematopoietic stem cell dormancy and may play a similar role in BCa cells.
  • TIE2 is a target in anti-angiogenic therapies, raising concerns about potentially reactivating dormant BCa cells.

Purpose of the Study:

  • To investigate the role of TIE2 in the dormancy of breast cancer bone metastases.
  • To assess TIE2's impact on BCa cell proliferation, cell cycle, and chemoresistance.
  • To evaluate TIE2's effect on tumor growth and bone metastasis formation in vivo.

Main Methods:

  • Analysis of TIE2 expression in patient data.
  • In vitro studies using BCa cell lines to assess proliferation, cell cycle, and drug resistance.
  • In vivo experiments in mouse models to evaluate tumor growth and bone metastasis.

Main Results:

  • Higher TIE2 expression in BCa patients correlated with longer time to metastasis and improved survival.
  • TIE2 expression reduced BCa cell proliferation by upregulating CDKN1A and CDKN1B, inducing G0/G1 cell cycle arrest.
  • TIE2 conferred resistance to 5-Fluorouracil and reduced tumor growth and osteolytic bone metastasis in mice.

Conclusions:

  • TIE2 is sufficient to induce dormancy in breast cancer bone metastases both in vitro and in vivo.
  • TIE2 expression serves as a potential prognostic marker for BCa patients.
  • Caution is advised when using TIE2 inhibitors in clinical settings due to the risk of awakening dormant disseminated tumor cells.
Keywords:
TIE2bone metastasisbreast cancercancer relapsechemotherapy resistancedormancy

More Related Videos

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

13.8K
Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines06:00

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines

Published on: September 13, 2017

7.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.5K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K